1. Home
  2. ARMP vs FATE Comparison

ARMP vs FATE Comparison

Compare ARMP & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$5.76

Market Cap

125.7M

Sector

Health Care

ML Signal

HOLD

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.12

Market Cap

131.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARMP
FATE
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.7M
131.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ARMP
FATE
Price
$5.76
$1.12
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$9.00
$3.92
AVG Volume (30 Days)
69.4K
1.2M
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,054,000.00
$7,137,000.00
Revenue This Year
$4.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.66
52 Week High
$16.34
$2.22

Technical Indicators

Market Signals
Indicator
ARMP
FATE
Relative Strength Index (RSI) 46.09 50.29
Support Level $5.67 $1.03
Resistance Level $6.39 $1.17
Average True Range (ATR) 0.58 0.07
MACD -0.13 0.02
Stochastic Oscillator 18.49 62.03

Price Performance

Historical Comparison
ARMP
FATE

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: